EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients  by Ringbaek, Thomas et al.
Respiratory Medicine (2008) 102, 1563e1567ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedEuroQoL in assessment of the effect of pulmonary
rehabilitation COPD patientsThomas Ringbaek*, Eva Brøndum, Gerd Martinez, Peter LangePulmonary Rehabilitation Research Group, Department of Cardiology and Respiratory Medicine, University Hospital of
Copenhagen, Hvidovre, Denmark
Received 27 April 2008; accepted 12 June 2008
Available online 9 August 2008KEYWORDS
COPD;
Pulmonary
rehabilitation;
Quality of life* Corresponding author at: Hvidov
Cardiology and Respiratory Medicine,
E-mail address: ringbaek@dadlnet
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.06.016Summary
Background: The effect of pulmonary rehabilitation on EuroQol in COPD patients has not been
investigated previously.
Methods/materials: Two hundred and twenty nine consecutive COPD patients who had
completed a 7-week pulmonary rehabilitation programme were assessed with EuroQol five-
dimension questionnaire (EQ-5D), endurance shuttle walk test (ESWT), and the St George’s
Respiratory Questionnaire (SGRQ) before and after the programme, and at the 3-month
follow-up visit.
Results: Two hundred and two (88.4%) patients had FEV1 < 50% predicted and all but four
(1.7%) had dyspnoea score at least 3 on MRC scale. At completion of the programme, statistical
significant improvements were seen for ESWT 157.3 s; p < 0.001, EQ-5D utility score 0.019;
pZ 0.03, EQ-5D VAS 2.1; pZ 0.056, SGRQ total score 2.8 units; p < 0.001. The effects
of rehabilitation on ESWT and SGRQ were maintained at 3-month follow-up (158.9 s and
2.9 units), while the effect on EQ-5 utility decreased (0.013; pZ 0.18). At baseline, there
was a maximum score (‘‘ceiling effect’’) for EQ-5D utility and EQ VAS in 29 (12.7%) and five
(2.2%) of the patients, respectively. After rehabilitation these number increased to 41
(17.9%) and seven (3.1%).
Conclusions: In COPD patients receiving rehabilitation, responsiveness of EQ-5D utility was
poor. One explanation might be a ‘‘ceiling effect’’ of this instrument.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Pulmonary rehabilitation is an established treatment for
COPD patients, which improves both physical performancere Hospital, Department of
2650 Hvidovre, Denmark.
.dk (T. Ringbaek).
8 Elsevier Ltd. All rights reservedand health-related quality of life (HRQoL)1 However, not all
studies have shown improvements in HRQoL after rehabili-
tation.2 This may be related to the responsiveness of the
chosen HRQoL instrument. Typically, HRQoL is measured
by disease specific instruments, such as St. George Respira-
tory Questionnaire (SGRQ) and Chronic Respiratory Ques-
tionnaire (CRQ).1 With a generic HRQoL measure more
global issues related to HRQoL can be assessed, such as.
248 Completed 7 weeks rehabilitation and attended the 3-month 
follow-up visit
3 were unable to do the Shuttle Walk Test at the follow-up visit
16 were unable to answer either the SGRQ or the EQ-5D
(9 SGRQ; 10 EQ-5D)
229 Constituted the study group
Figure 1 Flow chart of patients completing 7-week pulmo-
nary rehabilitation and attended 3 month follow-up visit.
1564 T. Ringbaek et al.social role, mental health, and general well being. In addi-
tion, generic instruments make it possible to compare
HRQoL across different diseases. The EuroQoL five-
dimension questionnaire (EQ-5D), a generic preference-
based instrument, is increasingly used as global measures
of HRQoL in cost-effectiveness studies.3 It generates utility
scores, which can be used in calculation of quality-adjusted
life years (QALY). Few studies in COPD patients have used
EQ-5D as an outcome,4,5 and only three studies have exam-
ined the responsiveness of EQ-5D to intervention (lung
transplantation, self-management, and Tiotropium).6e8
and in particular, the effect of PR on EQ-5D in COPD
patients has not been evaluated previously.
In a comparison of different outcome measures, Harper
et al. found, that many COPD patients were unable to
complete the SGRQ, and that many patients at baseline
scored either minimum (‘‘floor effect’’) or maximum
(‘‘ceiling effect’’) in SF-36, a generic HRQoL instrument.9
The primary aim of the present study was to evaluate
the responsiveness of EQ-5D to pulmonary rehabilitation in
COPD patients. The secondary aims were to compare the
complete rates, ‘‘floor effect’’, and ‘‘ceiling effect’’ of
EQ-5D and SGRQ.
Methods
Rehabilitation programme
The programme used in this study is adopted from Glenfield
Hospital, University Hospital of Leicester.10 Patients
attended twice weekly for 7 weeks with each session lasting
2 h. The session was divided into 1 h of supervised training
and 1 hof education. Relaxation techniques, disease educa-
tion, dietary advise, benefits advise, energy conservation,
medication advise, chest clearance, and breathing control
techniques comprised the main components of the educa-
tion. The supervised aerobe training sessions consisted of
walking and cycling. Patients were instructed to exercise
at a level equal to 85% of predicted peak oxygen uptake
as calculated from the Incremental Shuttle Walk Test
(ISWT). During the 7-week programme total continuous
walking times (with 85% of maximal intensity) were
measured with a stopwatch and recorded in a diary both
at the supervised training sessions and during unsupervised
daily training at home. Their diary was looked over at the
supervised training sessions. After the 7-week programme
patients were asked to continue the self-monitored daily
exercise at home as the only maintenance training. In addi-
tion, they received an illustrated folder with some of the
exercises included in the supervised sessions. When the
weather prevented them from walking outside, they were
encouraged to use the stairs in their apartments or to do
the exercises from the folder. Patients were advised to
increase the duration of the walk rather than the intensity.
Selection of patients
Two hundred and twenty nine consecutive patients consti-
tuted our study group (Fig. 1). Eligibility criteria included:
stable COPD (forced expiratory volume in 1 s (FEV1) <80%
and FEV1/forced vital capacity <70%; motivated forpulmonary rehabilitation; completion of a 7-week rehabili-
tation programme and followed-up 3 months later. Exclu-
sion criteria were: significant musculo-skeletal, cardiac,
or cognitive problems.
Outcome measures
Measurements were made before and after the programme,
and at 3 month follow-up. Endurance Shuttle Walk Test
(ESWT), EQ-5D, and SGRQ were the outcomes. An Incre-
mental Shuttle Walk Test (ISWT) was used to measure the
maximal exercise performance. The ESWT measured the
sub-maximal exercise performance, when the patient
walked at a constant speed equating to 85% of predicted
peak oxygen uptake as calculated from the ISWT.
The SGRQ is a disease specific questionnaire, which
comprises of three domains (dyspnoea, impact, and
activity) and has been valid, reproducible, and responsive
in patients with COPD.11
The EQ-5D is a self-administered generic instrument in
two sections, a descriptive and a valuation section.3 The
first section measures the following five-dimensions of
health: mobility; self-care; usual activities; pain/
discomfort; and anxiety/depression (EQ-5D utility). Each
dimension is divided into the following three levels of func-
tioning: no problems; some problems; and extreme prob-
lems. From these five answers a single index is derived on
a scale anchored at 1, which represents perfect health
and 0, which represents death. The second section is
a visual analogue scale measuring global health (EQ-5D
VAS). It is presented in the form of a thermometer with
100 intervals, in which 100 represent the best imaginable
state and 0 the worst imaginable state. We asked patients
to reflect the health status in their score as it was the
day of examination.
Statistics
Data were analysed in the statistical package (SPSS) version
12.0 SPSS Inc. (Chicago, USA). Analysis of variance (ANOVA)
was used to test the difference over time. Non-parametric
statistics (Wilcoxon) were applied in comparing EQ-5D
utility scores and ESWT because of non-normal distribution.
The theory of Wilcoxon signed-rank test is that the absolute
values of the differences between observations are ranked
from smallest to largest (rank 1 to the smallest, rank 2 to
the next smallest, and so on). If the null hypothesis is true,
the sum of the ranks of the positive differences should be
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Effect of pulmonary rehabilitation on quality of life 1565about the same as the sum of the ranks of the negative
differences. Note that this is different from the null
hypothesis of the paired t-test, which is that the mean
difference between pairs is zero. A two-sided p-value of
<0.05 was considered significant.
Results
Patients had severe airflow limitation (88.4% had FEV1 less
than 50% of predicted value) and dyspnoea while walking
(98.3% had at least MRC score 3) (Table 1, Fig. 2). Comple-
tion rates for SGRQ and EQ-5D were 96.3% and 95.1%,
respectively. After supervised rehabilitation, statistical
significant improvements were seen for ESWT 157.3 s
(p < 0.001), EQ-5D utility score 0.019 (pZ 0.034), SGRQ
total score 2.8 (p < 0.001), but not for EQ-5D VAS 2.1
(pZ 0.56) (Table 2). At 3-month follow-up the effects on
ESWT and SGRQ were maintained, while the effects on
EQ-5D were no longer present (Table 2).
At baseline, there was a ‘‘ceiling effect’’ for EQ-5D
utility and EQ VAS in 29 (12.7%) and 5 (2.2%) of the patients,
respectively. After rehabilitation, these numbers increased
to 41 (17.9%) and 7 (3.1%), and at follow-up, the numbers
were 45 (19.7%) and 2 (0.9%). There was no ‘‘ceiling effect’’
for SGRQ-total score. Patients who scored maximum for
EQ-5D utility at baseline had a mean FEV1 37.8%, MRC score
3.2, ESWT 201 s, and SGRQ-total score 42.7 units.
Discussion
The 7-week supervised pulmonary rehabilitation pro-
gramme improved EQ-5D slightly. However, this effect
was not maintained at 3-month follow-up. In contrast, the
positive effects on exercise tolerance and disease specific
health status remained unchanged.
The effect of rehabilitation on EQ-5D has not previously
been studied. The gain in EQ-5D utility score of our
rehabilitation programme was comparable to the fall seen
after 6 months in COPD patients, who acted as controls in
a study of self-management.7 In that study, self-Table 1 Patients’ characteristics at baseline for patients
who completed the 3-month follow-up period
Age, years 69.1 (8.1)
Gender, % males 31.9
FEV1 %-predicted value (nZ 225) 34.1 (12.2)
Body mass index, kg/m2 (nZ 226) 24.8 (5.3)
Current smokers, % (nZ 228) 19.7
Package years (minimumemaximum)
(nZ 226)
38.0 (0e100)
Musculo-skeletal diseases, % 21.8
Cardiac co-morbidity, % 29.7
Systemic corticosteroid, % 10.9
Long-term oxygen therapy, % 9.2
Oxygen saturation at rest and with air, % 94.0 (2.1)
Medical Research Council (MRC)
dyspnoea score (minimumemaximum)
3.7 (2e5)
Continuous variables are presented as mean (SD) unless other-
wise indicated.
0,000 0,200 0,400 0,600 0,800 1,000
score
0
Figure 2 Distribution of endurance shuttle walk time (ESWT)
(a) and EQ-5D (b) at baseline.management didn’t changed the EQ-5D utility score.7 Not
surprisingly, lung transplantation improved EQ-5D utility
score considerably more (approximately 0.35).6 Tiotropium
was associated with statistically significant improvements
in the visual analogue component of the EQ-5D and with
non-statistically significant trends in the utility scores.8
Only one study has provided information on minimum clin-
ically important difference (MCID) for the EQ-5D. Walters &
Brazier analysed eight longitudinal studies in 11 patient
groups that used both EQ-5D and SF-6D.12 They suggested
that the MCID for the EQ-5D was 0.074 (range
0.011e0.140). Looking specifically at COPD patients (in
total 55 patients) the MCID was negative! More studies are
needed to determine the MCID for EQ-5D.
Table 2 The effect of 7-week rehabilitation on endurance shuttle walk time (ESWT), SGRQ, and EuroQol 5-dimension ques-
tionnaire (EQ-5D)
Pre-rehab. Post-rehab. 3-month follow-up p-value
Pre-rehab. vs
post-rehab.
Pre-rehab. vs
3-month follow-up
EQ-5D utility score 0.759 (0.174) 0.778 (0.180) 0.771 (0.192) 0.034 0.18
EQ-5D VAS 58.6 (16.6) 60.7 (19.0) 59.2 (17.8) 0.056 0.30
SGRQ-total score 55.7 (12.9) 52.9 (13.3) 52.8 (14.4) <0.001 0.001
ESWT, s 172.3 (76.6) 329.6 (289.8) 331.2 (345.2) <0.001 <0.001
Variables are presented as mean (SD).
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Although, their patients had the same mean EQ-5D utility
score, they had higher EQ-5D VAS score (64.8) and FEV1
(48% of predicted). Compared to the study of Maninkhof
et al. where the effect of self-management was investi-
gated, our patients had worse SGRQ-total score 55.7 vs
37.2 and EQ-5D utility score 0.76 vs 0.81.7
In accordance with other studies, we found that
a disease specific instrument is more responsive than
a generic measure, when used for evaluation of PR.2,14e16
Yet, there are several reasons for also using generic instru-
ments: (1) a disease specific instrument may fail to capture
all aspects of HRQoL, e.g. co-morbidities such as cardiac
and musculo-skeletal problems, and side effects of inter-
vention; (2) generic instruments allow comparisons of
HRQoL across different diseases; and (3) utility instruments
can be used in economic evaluation.
The ideal health status instrument should be valid,
reliable, and responsive, and besides it should not be
expensive to use or too difficult or time consuming to
answer/fill in for the patient. In our study, completion rates
for SGRQ and EQ-5D were very high. This is in line with
findings from other studies.17,18 Sta˚hl et al. showed that
only 10e20% of the patients reported difficulty with
completing SGRQ and EQ-5D,17 and in a study of 573
patients with various chronic diseases, 60e75% of the
respondents found EQ-5D easy to respond to and easy to
understand.18 In contrast, Harper et al. found a completion
rate of only 30% for SGRQ-total score, but 92% for EQ-5D.9
Despite decreased FEV1 %-predicted, physical perfor-
mance, and SGRQ-total score, 12.7% of our patients scored
maximum at baseline for EQ-5D utility, and many more
were in the top category of each of the five-dimensions.
Similar results were found in a data set of 2436 cases,
covering patients with various diseases, where 10% of the
observations showed a maximum score (full health).19 The
consequence of this ‘‘ceiling effect’’ is less room for
improvement. It is possible that the responsiveness of
EQ-5D is better in patients with more severe COPD, where
the ‘‘ceiling effect’’ is expected to be less frequent.
In an attempt to minimise the ‘‘floor effect’’ and the
‘‘ceiling effect’’ and to improve responsiveness of EQ-5D,
a 15-dimension (15D) questionnaire each with five levels
instead of three levels has been developed.20 So far, it
has only been used in one study of COPD patients.21 Change
in EQ-5D, 15D, and SF-36 over a 1-year period was assessed
in 59 COPD patients from an outpatient. Compared to
EQ-5D, the ‘‘ceiling effect’’ was much less pronounced
for 15D, and it seemed more responsive.21 The 15D needsto be tested in larger studies and different groups of
COPD patients.
In conclusion, SGRQ is more responsive than the EQ-5D
to measure the effect of outpatient rehabilitation in COPD
patients. Completion rates were high for both instruments.
There was no ‘‘floor effect’’ but a significant ‘‘ceiling
effect’’ for EQ-5D, which might explain the poor respon-
siveness of this instrument.
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